| Serelaxin | acute heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death or hospitalization | no data | | Cardiovascular death or hospital admission for CHF | no data | | heart failure death | no data | | hospitalisation for cardiovascular causes | no data | | CV death, MI hospitalization for HF | no data | | Cardiovascular death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Pre-RELAX-AHF, 2009 | intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily | placebo | Patients hospitalized with acute heart failure | | RELAX-AHF, 2013 | 48-h intravenous infusions of placebo or serelaxin (30 ìg/kg per day) within 16 h from presentation | placebo (on top stnadard care) | patients admitted to hospital for acute heart failure |
| |
